drugset / Trial / NCT04163575
Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Phase 1/2
Unknown
100 enrolled
Kecellitics Biotech Company Ltd
Hebei Yanda Ludaopei Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the safety, efficacy and duration of response of CD22 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD22+ haematological malignancies.
Timeline
- Start
- 2020-02-01
- Primary completion
- 2021-07-01
- Completion
- 2022-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-CD22-CAR | Cell therapy | — | — |